Search results for "cance"

showing 10 items of 12092 documents

Design, synthesis and biological evaluation of new anticancer drugs: FGFR inhibitors

2021

Fibroblast growth factor receptors (FGFRs) constitute a family of tyrosine kinases receptors (RTKs) that exert pivotal physiological functions in human embryonic and adult tissues. Hyperactivated FGFR signaling drives tumorigenesis in multiple cancer types, including lung and brain cancers. Great effort has been laid on the development of new compounds that specifically target the FGFR axis. However, cancer cell- based and microenvironmental resistance mechanisms against FGFR inhibitors often arise and are currently poorly understood. Furthermore, FGFR-targeted therapy often presents different side effects, e due to the broad biological spectrum of the FGFR signaling axis as well as to its …

DesignhypoxiabrainglioblastomatransitionAnticancer drugs FGFR Drug design Ubiquitin Brain tumor Glioblastoma Lung cancer NSCLC SCLC Copper complexes Hypoxia activated drugs Metal drugsSettore BIO/11 - Biologia MolecolareSettore CHIM/08 - Chimica Farmaceuticalungmetal complexeFGFR1Settore CHIM/03 - Chimica Generale E InorganicacopperSettore BIO/10 - BiochimicaFGFR4Settore BIO/14 - Farmacologiacancersynthesi
researchProduct

The synergistic effect exerted by the HDAC inhibitor SAHA and the sesquiterpene lactone parthenolide on triple negative breast canc er cells

2014

Triple-negative breast cancer (TNBC) is a subtype o f breast cancer, insensitive to endocrine therapy. Chemotherapy is the main form of treatment, but is accompanied by a high rate of recidivism. The sesquiterpene lactone Parthenolide (PN) exerts a cy totoxic effect on MDA-MB231 cells, a TNBC cell line (1), but was ineffective at low doses (2-5μM). This repr esents an obstacle for a therapeutic utilization of PN. We supposed, in line with other authors (2), that PN c auses a protective response, which at low doses pre vails on the cytotoxic effect. With the aim of inhibiting this protective effect we have shown that pre-trea tment of MDA-MB231 cells with SAHA (2-5μM), an histone deace tylat…

triple negative breast cancer cells parthenolide istone deacetylates inhibitor apoptosis
researchProduct

Molecular markers and endometrial cancer

2022

None

molecular markersprecision medicineendometrial cancerMolecular markerendometrial cancer; molecular markers; precision medicinePrecision medicine.Settore MED/40 - Ginecologia E Ostetricia
researchProduct

P3‐271: Presenilin‐1 (PS1) and amyloid precursor protein (APP) mutations present in mouse models of Alzheimer's disease in their response to γ‐secret…

2009

biologyEpidemiologyChemistryHealth PolicyBACE1-ASP3 peptideDiseasePresenilinBiochemistry of Alzheimer's diseasePsychiatry and Mental healthCellular and Molecular NeuroscienceDevelopmental NeuroscienceAlpha secretasebiology.proteinCancer researchAmyloid precursor proteinNeurology (clinical)Geriatrics and GerontologyAmyloid precursor protein secretaseAlzheimer's & Dementia
researchProduct

2019

Parthenolide (PT) is a sesquiterpene lactone isolated from Tanacetum parthenium. In this study, PT showed varying cytotoxic effects against different solid tumor cell lines. HCT116 (p53+/+) colon carcinoma cells and their parental HCT116 knockout p53 (p53-/-) cell lines showed a resistance degree of 2.36. On the other hand, wild-type U87.MG cells or cells transfected with a deletion-activated EGFR cDNA (U87.MGΔEGFR) exhibited slight sensitivity toward PT. Multidrug-resistant MDA-MB-231-BCRP cells were even more sensitive toward PT than sensitive MDA-MB-231-pcDNA cells with a resistance degree of 0.07 (collateral sensitivity). To the best of our knowledge, hypersensitivity (collateral sensit…

0301 basic medicinePharmacologyNF-κBIκB kinaseTransfection03 medical and health scienceschemistry.chemical_compoundIκBα030104 developmental biology0302 clinical medicinechemistryCell culture030220 oncology & carcinogenesisGene expressionCancer researchCytotoxic T cellPharmacology (medical)ParthenolideFrontiers in Pharmacology
researchProduct

2021

Objective: Radical prostatectomy (RP) is a frequent treatment for men suffering from localized prostate cancer (PCa). Whilst offering a high chance for cure, it does not come without a significant impact on health-related quality of life. Herein we review the common adverse effects RP may have over the course of time.Methods: A collaborative narrative review was performed with the identification of the principal studies on the topic. The search was executed by a relevant term search on PubMed from 2010 to February 2021.Results: Rates of major complications in patients undergoing RP are generally low. The main adverse effects are erectile dysfunction varying from 11 to 87% and urinary incont…

medicine.medical_specialtyUrinary continencebusiness.industryProstatectomymedicine.medical_treatment030232 urology & nephrologyUrinary incontinencemedicine.disease03 medical and health sciencesProstate cancer0302 clinical medicineErectile dysfunctionQuality of life030220 oncology & carcinogenesismedicineSurgeryMajor complicationmedicine.symptomAdverse effectbusinessIntensive care medicineFrontiers in Surgery
researchProduct

Phase Ib Trial Trial of Rg7116, a Glycoengineered Monoclonal Antibody Targeting Her3, in Combination with Cetuximab or Erlotinib in Patients with Adv…

2014

ABSTRACT Aim: To evaluate the safety profile of RG7116 in combination with cetuximab or erlotinib. Methods: Patients (pts) with advanced or metastatic carcinomas with centrally confirmed HER3 protein expression were included. RG7116 plus cetuximab (400 mg/m2 followed by 250 mg/m2 qw IV) and RG7116 plus erlotinib (150 mg/day p.o.) combinations were evaluated in a dose escalation study with “3 + 3” design at a starting dose of 400 mg IV of RG7116 in a q2w regimen. Results: Twenty-seven pts were enrolled in 5 cohorts (400 to 2000 mg) in the cetuximab arm. One dose-limiting toxicity (DLT) of grade 3 dehydration was reported in the 800-mg cohort. Twenty-seven pts were enrolled in 4 cohorts (400 …

Oncologymedicine.medical_specialtyCetuximabbusiness.industryColorectal cancerHematologymedicine.diseaseRashHypokalemiaSurgeryRegimenOncologyInternal medicineMedicineErlotinibmedicine.symptombusinessOvarian cancerAdverse effectneoplasmsmedicine.drugAnnals of Oncology
researchProduct

Abstract 2141: Stromal SPARC deficiency skews prostate cancer toward neuroendocrine differentiation

2018

Abstract Tumor progression is a multifaceted process in which, complex interactions between tumor and different types of stromal cells and extracellular matrix components, actively contribute to its phenotypic heterogeneity. Among extracellular matrix proteins, secreted protein acidic and rich in cysteine (SPARC) has been deeply studied since conflicting reports have described its expression to be either increased or decreased in different cancer settings, also depending on whether it is produced by the neoplasm or by the neighboring stroma. Nevertheless, the different contribution of tumor- or stromal-derived SPARC in prostate tumor microenvironment has not been addressed at least for tumo…

Cancer ResearchTumor microenvironmentStromal cellCancerBiologymedicine.diseaseNeuroendocrine differentiationProstate cancerOncologyTumor progressionmedicineCancer researchAdenocarcinomaTrampCancer Research
researchProduct

Les cancers du rein non à cellules claires : caractéristiques clinico-biologiques et prise en charge thérapeutique hors chirurgie

2020

Resume Les cancers du rein non a cellules claires representent pres de 25 % de l’ensemble des cancers du rein, et constituent un groupe de tumeurs tres heterogenes a la fois en termes de varietes histologiques, mais egalement d’anomalies biologiques oncogeniques. La presentation clinique ainsi que le pronostic des patients sont egalement tres variables. Compte tenu de la rarete de chaque entite tumorale, il n’existe que tres peu d’essais cliniques ayant porte sur une variete bien definie de cancer non a cellules claires. Ceci rend difficile l’interpretation de ces etudes, et donc l’emission de recommandations claires de prise en charge medicale pour la maladie avancee. Dans cet article, les…

0301 basic medicineGynecologyCancer Researchmedicine.medical_specialtybusiness.industryHematologyGeneral Medicine03 medical and health sciences030104 developmental biology0302 clinical medicineOncology030220 oncology & carcinogenesisMedicineRadiology Nuclear Medicine and imagingPapillary carcinomabusinessRenal carcinomaBulletin du Cancer
researchProduct

Abstract A02: Neuroblastoma patient-derived orthotopic xenografts: Clinically relevant models for drug testing

2016

Abstract Widespread metastasis is a major problem for the treatment of high-risk neuroblastoma. Relevant neuroblastoma animal models are hence needed to study and target high-risk metastatic neuroblastoma. We developed neuroblastoma patient-derived orthotopic xenografts (PDXs) using viably cryopreserved or fresh patient neuroblastoma fragments which were implanted orthotopically into immunodeficient NSG mice. Immunohistochemistry showed that PDXs retain neuroblastoma markers and a highly infiltrative growth pattern. Importantly, we found distant metastasis to lungs, liver and bone marrow. Single nucleotide polymorphism array analysis confirmed that PDXs maintain patient-specific chromosomal…

Cancer ResearchPathologymedicine.medical_specialtyTumor microenvironmentOncogenebusiness.industryCancermedicine.diseasePediatric cancerMetastasisLymphatic systemmedicine.anatomical_structureOncologyNeuroblastomamedicineBone marrowbusinessCancer Research
researchProduct